Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Integrilin scheduled for review

Jan. 16, 1997

New compounds for heparin reversal disclosed by University of Michigan

Jan. 14, 1997

Schering-Plough selects Corvas thrombin inhibitor for development

Jan. 13, 1997

NO donors claimed by Searle for cardiovascular applications

Jan. 13, 1997

Fibrinogen receptor antagonists under development at E. Merck

Jan. 10, 1997

Thrombin-binding anticoagulant disclosed by Japanese scientists

Jan. 10, 1997

Boehringer Mannheim clot-busting drug introduced in first market

Jan. 7, 1997

Thrombolytic agent introduced in Germany

Dec. 31, 1996

BMS describes thrombin-activatable plasminogen activator

Dec. 31, 1996

Novel thrombin inhibitors in development at LG Chemical

Dec. 31, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...